UroGen Pharma Ltd
URGN
13.40USD+0.17 (+1.28%)Market ClosedWatchlist
Market Summary
USD13.40+0.17
Market Closed1.28%
URGN Stock Price
View Fullscreen
URGN RSI Chart
URGN Valuation
URGN Price/Sales (Trailing)
URGN Profitability
URGN Fundamentals
URGN Revenue
URGN Earnings
Price Action
Last 7 days
4.4%
Last 30 days
17.4%
Last 90 days
-20.5%
Trailing 12 Months
56.0%
How does URGN drawdown profile look like?
URGN Financial Health
URGN Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 68.0M | 72.5M | 77.3M | 0 |
| 2022 | 54.1M | 57.7M | 62.4M | 64.4M |
| 2021 | 19.3M | 31.9M | 39.8M | 48.0M |
| 2020 | 0 | 0 | 0 | 11.8M |
| 2019 | 0 | 0 | 0 | 0 |
| 2018 | 8.6M | 9.0M | 1.5M | 1.1M |
| 2017 | 15.2M | 12.8M | 10.5M | 8.2M |
| 2016 | 0 | 0 | 0 | 17.5M |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for URGN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Aug 31, 2023 | smith jason drew | acquired | - | - | 8,334 | general counsel |
| Aug 31, 2023 | smith jason drew | sold | -68,438 | 18.01 | -3,800 | general counsel |
| Jul 26, 2023 | cohen fred e | acquired | 661,494 | 9.54 | 69,339 | - |
| Jan 31, 2023 | schoenberg mark | acquired | - | - | 3,833 | chief medical officer |
| Jan 31, 2023 | barrett elizabeth a. | acquired | - | - | 18,333 | chief executive officer |
| Jan 31, 2023 | smith jason drew | sold | -16,556 | 10.12 | -1,636 | general counsel |
| Jan 31, 2023 | smith jason drew | acquired | - | - | 3,333 | general counsel |
| Jan 31, 2023 | schoenberg mark | sold | -19,228 | 10.12 | -1,900 | chief medical officer |
| Jan 20, 2023 | schoenberg mark | acquired | 613,385 | 5.00 | 122,677 | chief medical officer |
| Oct 31, 2022 | schoenberg mark | acquired | - | - | 500 | chief medical officer |
Which funds bought or sold URGN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 666 | 133,111 | 147,301 | -% |
| Nov 15, 2023 | MORGAN STANLEY | added | 76.52 | 905,326 | 1,556,890 | -% |
| Nov 15, 2023 | Opaleye Management Inc. | reduced | -43.86 | -1,416,300 | 4,483,200 | 1.46% |
| Nov 15, 2023 | GSA CAPITAL PARTNERS LLP | new | - | 143,000 | 143,000 | 0.01% |
| Nov 15, 2023 | Annandale Capital, LLC | reduced | -2.96 | 273,000 | 1,146,000 | 0.28% |
| Nov 15, 2023 | JANE STREET GROUP, LLC | reduced | -24.69 | 2,675 | 140,899 | -% |
| Nov 14, 2023 | WELLINGTON MANAGEMENT GROUP LLP | new | - | 981,582 | 981,582 | -% |
| Nov 14, 2023 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -33.67 | -6,877 | 60,481 | -% |
| Nov 14, 2023 | LAZARD ASSET MANAGEMENT LLC | new | - | 46,000 | 46,000 | -% |
| Nov 14, 2023 | MILLENNIUM MANAGEMENT LLC | added | 43.54 | 1,875,220 | 3,863,750 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of UroGen Pharma Ltd
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Sep 15, 2023 | great point partners llc | 8.51% | 2,620,545 | SC 13G | |
| Aug 04, 2023 | monograph capital holdings advisors, llc | 5.1% | 1,572,327 | SC 13D | |
| Jun 12, 2023 | menora mivtachim holdings ltd. | 12.45% | 2,919,002 | SC 13G/A | |
| Feb 13, 2023 | stonepine capital management, llc | 5.7% | 1,304,947 | SC 13G/A | |
| Dec 01, 2022 | stonepine capital management, llc | 5.2% | 1,196,908 | SC 13G | |
| Jul 08, 2022 | blackrock inc. | 1.5% | 340,412 | SC 13G | |
| Feb 14, 2022 | wildcat capital management, llc | 2.4% | 533,139 | SC 13G/A | |
| Feb 14, 2022 | credit suisse ag/ | 4.84% | 1,085,749 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 1.06% | 238,008 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 7.7% | 1,728,094 | SC 13G/A |
Recent SEC filings of UroGen Pharma Ltd
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Nov 14, 2023 | 10-Q | Quarterly Report | |
| Nov 14, 2023 | 8-K | Current Report | |
| Nov 14, 2023 | S-8 | Employee Benefits Plan | |
| Sep 15, 2023 | EFFECT | EFFECT | |
| Sep 15, 2023 | SC 13G | Major Ownership Report | |
| Sep 13, 2023 | CORRESP | CORRESP | |
| Sep 12, 2023 | UPLOAD | UPLOAD | |
| Sep 11, 2023 | 8-K | Current Report | |
| Sep 08, 2023 | 4 | Insider Trading | |
| Sep 08, 2023 | 4 | Insider Trading |
Peers (Alternatives to UroGen Pharma Ltd)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
HILS | 31.4B | - | 4.92% | 426363.59% | -3.6K | 218.4K | - | -102.45% |
MRNA | 30.7B | 10.7B | 11.84% | -53.56% | -8.86 | 2.88 | -53.67% | -129.46% |
ALNY | 22.0B | 1.7B | 4.71% | -20.32% | -43.06 | 12.74 | 79.37% | 56.87% |
BMRN | 17.7B | 2.3B | 23.54% | -7.88% | 120.62 | 7.68 | 15.05% | 75.21% |
INCY | 12.4B | 3.6B | 1.56% | -32.86% | 29.22 | 3.44 | 8.35% | -51.49% |
| MID-CAP | ||||||||
APLS | 7.5B | 272.9M | 38.55% | 34.32% | -12.3 | 27.31 | 141.38% | 4.43% |
BBIO | 5.6B | - | 16.25% | 246.63% | -9.66 | 48.33 | 54.84% | -12.96% |
ACAD | 3.5B | 631.9M | -10.80% | 43.56% | -23.57 | 5.55 | 23.54% | 31.53% |
AXSM | 3.3B | 223.4M | 11.07% | -7.88% | -16.25 | 14.68 | - | -26.24% |
ARWR | 2.6B | 240.7M | -11.66% | -25.68% | -12.44 | 10.6 | -1.03% | -16.59% |
| SMALL-CAP | ||||||||
CPRX | 1.5B | 348.4M | 7.85% | -14.88% | 24.07 | 4.29 | 81.69% | -7.29% |
NVAX | 662.5M | 1.0B | -19.01% | -66.75% | -1.21 | 0.63 | -43.15% | 58.48% |
INO | 100.5M | 6.4M | -2.56% | -78.77% | -0.61 | 15.6 | -44.11% | 50.48% |
IBIO | 42.3M | - | 410.00% | -4.38% | -0.65 | - | - | -29.23% |
CRBP | 26.3M | - | 17.86% | 4717.52% | -0.55 | - | - | -13.74% |
UroGen Pharma Ltd News
Latest updates
Financials for UroGen Pharma Ltd
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | -1.4% | 20,852,000 | 21,139,000 | 17,192,000 | 18,092,000 | 16,097,000 | 16,604,000 | 13,564,000 | 16,174,000 | 11,351,000 | 13,032,000 | 7,485,000 | 7,966,000 | 3,461,000 | 372,000 | 310,000 | 248,000 | 186,000 | 124,000 | 62,000 | - | 283,000 |
| Cost Of Revenue | -3.1% | 2,367,000 | 2,443,000 | 2,265,000 | 2,263,000 | 2,020,000 | 1,846,000 | 1,525,000 | 1,589,000 | 1,244,000 | 1,427,000 | 897,000 | 652,000 | 309,000 | 48,000 | - | - | - | - | - | - | 1,055,000 |
| Gross Profit | -1.1% | 18,485,000 | 18,696,000 | 14,927,000 | 15,829,000 | 14,077,000 | 14,758,000 | 12,039,000 | 14,585,000 | 10,107,000 | 11,605,000 | 6,588,000 | 7,314,000 | 3,152,000 | 324,000 | - | - | - | 18,000 | - | - | -772,000 |
| S&GA Expenses | -3.3% | 21,755,000 | 22,494,000 | 24,474,000 | 21,634,000 | 19,071,000 | 20,833,000 | 21,300,000 | 21,418,000 | 21,624,000 | 22,304,000 | 22,189,000 | 22,163,000 | 22,065,000 | 24,018,000 | 21,973,000 | 19,745,000 | 13,972,000 | 13,775,000 | 12,707,000 | 12,552,000 | 10,743,000 |
| R&D Expenses | -11.7% | 10,230,000 | 11,584,000 | 12,498,000 | 14,477,000 | 13,093,000 | 12,640,000 | 12,696,000 | 13,082,000 | 11,923,000 | 12,124,000 | 10,513,000 | 12,405,000 | 10,211,000 | 8,106,000 | 16,588,000 | 20,094,000 | 9,481,000 | 9,996,000 | 9,726,000 | 11,465,000 | 9,574,000 |
| EBITDA Margin | - | - | - | -1.61 | -1.66 | -1.70 | -1.93 | -2.05 | -2.26 | -2.72 | -3.36 | -6.20 | -10.14 | -14.99 | -80.63 | -76.24 | -76.32 | -53.65 | - | - | - | - |
| Income Taxes | -116.7% | -9,000 | 54,000 | 21,000 | 689,000 | 709,000 | 32,000 | 325,000 | 1,137,000 | - | 312,000 | - | 3,374,000 | - | - | - | - | - | - | - | - | - |
| Earnings Before Taxes | 9.1% | -21,888,000 | -24,082,000 | -30,192,000 | -28,180,000 | -25,122,000 | -26,659,000 | -28,067,000 | -27,315,000 | -30,211,000 | -25,910,000 | -25,935,000 | -27,152,000 | -28,816,000 | -31,349,000 | - | - | - | - | - | - | - |
| EBT Margin | - | - | - | -1.62 | -1.68 | -1.72 | -1.95 | -2.06 | -2.28 | -2.74 | -3.38 | -6.49 | -10.60 | -15.70 | -84.27 | -80.39 | -80.39 | -57.75 | - | - | - | - |
| Net Income | 9.4% | -21,879,000 | -24,136,000 | -30,213,000 | -28,869,000 | -25,831,000 | -26,691,000 | -28,392,000 | -28,452,000 | -30,211,000 | -26,222,000 | -25,935,000 | -30,526,000 | -28,816,000 | -31,349,000 | -37,793,000 | -38,973,000 | -22,252,000 | -22,477,000 | -21,444,000 | -23,716,000 | -20,533,000 |
| Net Income Margin | - | - | - | -1.64 | -1.71 | -1.75 | -1.97 | -2.09 | -2.31 | -2.83 | -3.49 | -6.05 | -10.89 | -17.86 | -87.61 | -92.89 | -80.39 | -68.72 | - | - | - | - |
| Free Cashflow | - | - | - | -25,830,000 | -21,765,000 | -17,765,000 | -24,262,000 | -24,021,000 | -20,272,000 | -18,670,000 | -19,014,000 | -27,688,000 | -21,414,000 | -25,740,000 | -24,216,000 | -35,731,000 | -26,192,000 | -12,577,000 | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | 103.1% | 194 | 95.00 | 113 | 136 | 128 | 146 | 166 | 120 | 135 | 154 | 97.00 | 122 | 140 | 161 | 167 | 202 | 227 | 239 | 252 | 104 | 113 |
| Current Assets | 123.9% | 182 | 81.00 | 96.00 | 129 | 122 | 140 | 161 | 114 | 125 | 140 | 93.00 | 116 | 129 | 130 | 122 | 149 | 160 | 191 | 248 | 102 | 111 |
| Cash Equivalents | 492.8% | 119 | 20.00 | 37.00 | 55.00 | 29.00 | 81.00 | 105 | 44.00 | 55.00 | 63.00 | 40.00 | 53.00 | 25.00 | 36.00 | 26.00 | 50.00 | 66.00 | 90.00 | 247 | 101 | 109 |
| Inventory | 0.3% | 5.00 | 5.00 | 5.00 | 4.00 | 5.00 | 5.00 | 5.00 | 5.00 | 4.00 | 3.00 | 3.00 | 2.00 | 1.00 | 1.00 | - | - | - | - | - | - | - |
| Net PPE | -9.6% | 1.00 | 1.00 | 1.00 | 1.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 |
| Liabilities | 0.8% | 236 | 234 | 230 | 225 | 192 | 187 | 183 | 111 | 103 | 97.00 | 21.00 | 26.00 | 19.00 | 18.00 | 16.00 | 22.00 | 16.00 | 14.00 | 12.00 | 13.00 | 9.00 |
| Current Liabilities | -3.7% | 26.00 | 27.00 | 25.00 | 24.00 | 19.00 | 18.00 | 19.00 | 22.00 | 20.00 | 19.00 | 17.00 | 21.00 | 18.00 | 16.00 | 14.00 | 19.00 | 14.00 | 12.00 | 10.00 | 13.00 | 9.00 |
| LT Debt, Non Current | 0.2% | 99.00 | 98.00 | 98.00 | 98.00 | 72.00 | 71.00 | 71.00 | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Shareholder's Equity | 69.7% | -41.99 | -138 | - | -89.36 | -63.29 | -40.91 | - | 8.00 | 32.00 | 56.00 | 76.00 | 96.00 | 121 | 143 | 150 | 180 | 211 | 225 | 240 | 90.00 | 104 |
| Retained Earnings | -3.5% | -653 | -631 | -607 | -577 | -548 | -522 | -495 | -467 | -438 | -408 | -382 | -356 | -326 | -297 | -265 | -228 | -189 | -166 | -144 | -122 | -99.15 |
| Additional Paid-In Capital | 24.0% | 611 | 493 | 491 | 488 | 485 | 481 | 479 | 476 | 470 | 465 | 459 | 453 | 446 | 439 | 416 | 408 | 400 | 391 | 384 | 213 | 203 |
| Shares Outstanding | 31.5% | 31.00 | 24.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 23.00 | 22.00 | 22.00 | 22.00 | 22.00 | 22.00 | 21.00 | 21.00 | 21.00 | 20.00 | 21.00 | 19.00 | 16.00 | 16.00 |
Cashflow (Last 12 Months)(In Thousands)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | 14.7% | -17,299 | -20,274 | -25,807 | -21,752 | -17,612 | -24,199 | -23,996 | -20,070 | -18,476 | -18,945 | -27,401 | -21,242 | -25,080 | -23,929 | -35,635 | -26,000 | -12,528 | -14,555 | -17,934 | -10,284 | -9,279 |
| Share Based Compensation | 0.1% | 2,224 | 2,222 | 2,286 | 2,368 | 2,440 | 2,823 | 2,949 | 5,357 | 5,515 | 6,046 | 6,195 | 6,526 | 6,763 | 7,119 | 7,617 | 8,065 | 7,243 | 7,212 | 7,447 | 8,877 | 9,515 |
| Cashflow From Investing | -89.2% | 401 | 3,720 | 6,270 | 23,108 | -35,493 | -151 | 13,596 | 9,125 | 10,660 | -30,740 | 15,024 | 49,465 | 13,234 | 17,514 | 13,025 | 9,296 | -12,659 | -142,186 | -44.00 | -26.00 | -333 |
| Cashflow From Financing | 81072.7% | 116,077 | 143 | 671 | 25,368 | 1,101 | -77.00 | 70,742 | -32.00 | -168 | 72,515 | 4.00 | 78.00 | 61.00 | 16,298 | 90.00 | 245 | 1,126 | 373 | 163,506 | 2,200 | -14.00 |
URGN Income Statement
2023-09-30Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Revenue | $ 20,852 | $ 16,097 | $ 59,183 | $ 46,265 |
| Cost of revenue | 2,367 | 2,020 | 7,075 | 5,391 |
| Gross profit | 18,485 | 14,077 | 52,108 | 40,874 |
| Operating expenses: | ||||
| Research and development expenses | 10,230 | 13,093 | 34,312 | 38,429 |
| Selling, general and administrative expenses | 21,755 | 19,071 | 68,723 | 61,204 |
| Operating loss | (13,500) | (18,087) | (50,927) | (58,759) |
| Financing on prepaid forward obligation | (5,479) | (4,819) | (16,047) | (16,478) |
| Interest expense on long-term debt | (3,815) | (2,694) | (11,129) | (5,215) |
| Interest and other income, net | 906 | 478 | 1,941 | 604 |
| Loss before income taxes | (21,888) | (25,122) | (76,162) | (79,848) |
| Income tax expense | 9 | (709) | (66) | (1,066) |
| Net Loss | (21,879) | (25,831) | (76,228) | (80,914) |
| Statements of Comprehensive Loss | ||||
| Net loss | (21,879) | (25,831) | (76,228) | (80,914) |
| Other comprehensive income (loss) | ||||
| Unrealized gain (loss) on investments | 20 | (99) | (27) | (130) |
| Comprehensive Loss | $ (21,859) | $ (25,930) | $ (76,255) | $ (81,044) |
| Net loss per ordinary share - basic and diluted (in dollars per share) | $ (0.68) | $ (1.13) | $ (2.89) | $ (3.56) |
| Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares) | 32,298,182 | 22,798,263 | 26,358,719 | 22,711,686 |
URGN Balance Sheet
2023-09-30Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 119,305 | $ 55,408 |
| Marketable securities | 28,114 | 44,556 |
| Restricted cash | 817 | 813 |
| Accounts receivable | 12,847 | 12,704 |
| Inventories | 5,002 | 4,325 |
| Prepaid expenses and other current assets | 16,038 | 11,101 |
| Total current assets | 182,123 | 128,907 |
| Non-current assets: | ||
| Property and equipment, net | 823 | 1,297 |
| Restricted deposit | 225 | 223 |
| Right of use assets | 1,905 | 2,452 |
| Marketable securities | 6,507 | 0 |
| Other non-current assets | 2,050 | 2,740 |
| Total Assets | 193,633 | 135,619 |
| Current liabilities: | ||
| Accounts payable and accrued expenses | 14,083 | 12,383 |
| Employee related accrued expenses | 8,152 | 8,257 |
| Other current liabilities | 3,553 | 3,276 |
| Total current liabilities: | 25,788 | 23,916 |
| Non-current liabilities: | ||
| Prepaid forward obligation | 107,276 | 98,923 |
| Long-term debt | 98,518 | 97,537 |
| Long-term lease liabilities | 1,026 | 1,586 |
| Uncertain tax positions liability | 3,018 | 3,018 |
| Total Liabilities | 235,626 | 224,980 |
| Commitments and Contingencies (Note 18) | ||
| Shareholders' Deficit: | ||
| Ordinary shares, NIS 0.01 par value, 100,000,000 shares authorized at September 30, 2023 and December 31, 2022; 30,854,778 and 23,129,953 shares issued and outstanding as of September 30, 2023 and December 31, 2022, respectively | 84 | 63 |
| Additional paid-in capital | 611,389 | 487,787 |
| Accumulated deficit | (653,332) | (577,104) |
| Accumulated other comprehensive loss | (134) | (107) |
| Total Shareholders' Deficit | (41,993) | (89,361) |
| Total Liabilities and Shareholders' Deficit | $ 193,633 | $ 135,619 |
| CEO | Ms. Elizabeth A. Barrett |
|---|---|
| WEBSITE | www.urogen.com |
| EMPLOYEES | 193 |